Trials / Terminated
TerminatedNCT04351191
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department · Other Government
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine Sulfate Regular dose | Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2 |
| DRUG | Hydroxychloroquine Sulfate Loading Dose | Hydroxychloroquine administered as a loading dose only |
| DRUG | Chloroquine | Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2 |
| DRUG | Placebo | Standard of Care plus placebo |
Timeline
- Start date
- 2020-04-15
- Primary completion
- 2020-08-23
- Completion
- 2020-08-30
- First posted
- 2020-04-17
- Last updated
- 2021-03-10
Locations
4 sites across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT04351191. Inclusion in this directory is not an endorsement.